Monograph Details
|
|
Central Nervous System
> Seizure disorders
|
|
ZONEGRAN |
| Manufacturer |
|
Eisai Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonamide. |
| Generic Name |
|
Zonisamide 25mg, 50mg, 100mg; caps. |
| Indications |
|
Adjunct in partial seizures. |
| Children |
|
<16yrs: not recommended. |
| Adults |
|
Swallow whole. ≥16yrs: initially 100mg once daily; may increase at intervals of at least 2 weeks by 100mg/day in 1 or 2 divided doses. Usual range: 100–400mg/day in 1 or 2 divided doses; usual max 600mg/day. |
| Precautions |
|
Discontinue or monitor closely if rash occurs. Renal failure: not recommended. Renal or hepatic impairment: titrate more slowly and monitor more frequently. Depression. Suicidal tendencies (monitor). Maintain adequate hydration. Exposure to extreme heat; monitor closely for oligohidrosis and hyperthermia (esp. children). Avoid abrupt cessation. Women of childbearing potential: use effective contraception. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Serum levels may be affected by CYP3A4 inducers or inhibitors. Caution with other drugs that interfere with temperature regulation (eg, anticholinergics, carbonic anhydrase inhibitors). |
| Adverse Reactions |
|
CNS effects (eg, somnolence, anorexia, dizziness, headache, agitation, ataxia, confusion, depression, insomnia, abnormal vision or speech), GI upset/pain, paresthesia, kidney stones; rarely: Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, oligohidrosis, hyperthermia. |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
